Complete Response Letter BLA 125745 (Jan 15, 2025)

Summary

The FDA has issued a Complete Response letter for Atara Biotherapeutics, Inc.'s Biologics License Application (BLA) for tabelecleucel, indicating that final approval cannot be granted due to unresolved deficiencies related to Chemistry, Manufacturing, and Controls (CMC) and inspectional observations. The FDA reserves comment on labeling until other issues are resolved.

Key points

• Adequately demonstrate corrections to FDA's inspectional observations issued at the conclusion of the pre-license inspection.
• Ensure the product and establishment listed in the BLA comply with the standards established in the BLA and the requirements prescribed in FDA regulations, including current good manufacturing practice requirements.
• Resubmit or withdraw the application within one year after the date of this letter.
• Fully address all listed deficiencies in any resubmission.
• Submit meeting requests as described in the guidance for industry Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products and CBER’s SOPP 8101.1.
• Corrections to FDA’s inspectional observations issued at the conclusion of the pre-license inspection have not been adequately demonstrated, may require additional review during a follow-up inspection, and, therefore, remain unresolved. CBER cannot determine pursuant to 21 CFR 601.20(a) and (d) that the product and establishment comply with BLA standards and current good manufacturing practice requirements.
• The agency reserves comment on the proposed labeling until the application is otherwise acceptable. Comments may be provided once other deficiencies are resolved and a proposed final labeling is submitted.

Cited reasons

• Unresolved Chemistry, Manufacturing, and Controls (CMC) Issues
• Labeling Comments Reserved
• The Biologics License Application (BLA) for tabelecleucel received a Complete Response Letter due to unresolved Chemistry, Manufacturing, and Controls (CMC) issues stemming from pre-license inspection observations. The agency cannot determine compliance with BLA standards and cGMP requirements. Labeling comments are reserved until these primary deficiencies are addressed.

Recommended actions

• Adequately demonstrate corrections to FDA's inspectional observations issued at the conclusion of the pre-license inspection.
• Ensure the product and establishment listed in the BLA comply with the standards established in the BLA and the requirements prescribed in FDA regulations, including current good manufacturing practice requirements.
• Resubmit or withdraw the application within one year after the date of this letter.
• Fully address all listed deficiencies in any resubmission.
• Submit meeting requests as described in the guidance for industry Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products and CBER’s SOPP 8101.1.

Deficiency summary

The Biologics License Application (BLA) for tabelecleucel received a Complete Response Letter due to unresolved Chemistry, Manufacturing, and Controls (CMC) issues stemming from pre-license inspection observations. The agency cannot determine compliance with BLA standards and cGMP requirements. Labeling comments are reserved until these primary deficiencies are addressed.

Findings

Regulatory context

Submission stage

final decision

Regulatory pathway

BLA

Impact

Impact score

0.95

Estimated delay

365 days

Estimated rework cost

$0

Subsequent action

resubmission

Strategic insights

The primary obstacle to approval is the failure to adequately resolve manufacturing and quality control deficiencies identified during a pre-license inspection, indicating non-compliance with cGMP. Labeling review is contingent upon the resolution of these critical CMC issues.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 5%